26,651 Shares in Grail, Inc. (NASDAQ:GRAL) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 26,651 shares of the company's stock, valued at approximately $476,000. Raymond James Financial Inc. owned about 0.08% of Grail at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. FNY Investment Advisers LLC bought a new stake in shares of Grail during the fourth quarter worth $26,000. Lindbrook Capital LLC acquired a new position in shares of Grail during the fourth quarter worth approximately $28,000. Wellington Shields Capital Management LLC bought a new position in Grail in the 4th quarter valued at $33,000. New York State Common Retirement Fund acquired a new stake in Grail in the fourth quarter worth about $59,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Grail in the 4th quarter valued at about $64,000.

Grail Price Performance

Shares of Grail stock traded up $6.90 during trading on Tuesday, hitting $42.89. 2,958,972 shares of the company were exchanged, compared to its average volume of 1,230,081. The firm's fifty day moving average price is $29.50 and its 200 day moving average price is $26.04. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.03) by $0.93. On average, equities analysts anticipate that Grail, Inc. will post -15.15 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, March 18th. Canaccord Genuity Group began coverage on Grail in a research note on Monday, April 21st. They issued a "buy" rating and a $32.00 price target on the stock.

Insider Activity

In other Grail news, President Joshua J. Ofman sold 2,109 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the completion of the transaction, the president now directly owns 559,673 shares of the company's stock, valued at approximately $17,461,797.60. The trade was a 0.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $56,659.20. Following the completion of the sale, the chief financial officer now owns 335,170 shares of the company's stock, valued at $10,457,304. This trade represents a 0.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 194,948 shares of company stock valued at $6,583,130 in the last quarter. Company insiders own 1.85% of the company's stock.

Grail Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.